Elsevier

Kidney International

Volume 86, Issue 2, August 2014, Pages 350-357
Kidney International

Basic Research
Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat

https://doi.org/10.1038/ki.2014.66Get rights and content
Under a Creative Commons license
open access

Many xenobiotics including the pharmacoenhancer cobicistat increase serum creatinine by inhibiting its renal active tubular secretion without affecting the glomerular filtration rate. This study aimed to define the transporters involved in creatinine secretion, applying that knowledge to establish the mechanism for xenobiotic-induced effects. The basolateral uptake transporters organic anion transporter OAT2 and organic cation transporters OCT2 and OCT3 were found to transport creatinine. At physiologic creatinine concentrations, the specific activity of OAT2 transport was over twofold higher than OCT2 or OCT3, establishing OAT2 as a likely relevant creatinine transporter and further challenging the traditional view that creatinine is solely transported by a cationic pathway. The apical multidrug and toxin extrusion transporters MATE1 and MATE2-K demonstrated low-affinity and high-capacity transport. All drugs known to affect creatinine inhibited OCT2 and MATE1. Similar to cimetidine and ritonavir, cobicistat had the greatest effect on MATE1 with a 50% inhibition constant of 0.99 μM for creatinine transport. Trimethoprim potently inhibited MATE2-K, whereas dolutegravir preferentially inhibited OCT2. Cimetidine was unique, inhibiting all transporters that interact with creatinine. Thus, the clinical observation of elevated serum creatinine in patients taking cobicistat is likely a result of OCT2 transport, facilitating intracellular accumulation, and MATE1 inhibition.

KEYWORDS

antibiotics
Cockcroft–Gault
creatinine
creatinine clearance
glomerular filtration rate
proximal tubule

Cited by (0)

E-IL, JH, RB, BPM, GB, TC, and ASR are employed by and are shareholders of Gilead Sciences, which is marketing cobicistat as part of the combination pill STRIBILD for the treatment of HIV. XZ, JH, AK, and YH are employed by Optivia Biotechnology a contract service provider of transporter-related assays including the proprietary Opti-Expression transfection technology used in these studies.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/

3

These authors contributed equally to this work.